prof. MUDr. Jiří Mayer, CSc.
Department head, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 3643, 3603 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 1619
2018
-
Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, year: 2018, volume: 18, edition: 2, DOI
-
Analysis of serum lipids, cardiovascular risk and indication for statin therapy at the start and during imatinib and nilotinib therapy in de novo CML patients, results from real life prosective study
Year: 2018, type: Conference abstract
-
Analýza sérových lipidů, kardiovaskulárního rizika a indikace k hypolipidemické terapii u nemocných s de novo CML léčených imatinibem - výsledky z prospektivní studie
Year: 2018, type: Conference abstract
-
Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin
Plos one, year: 2018, volume: 13, edition: 12, DOI
-
CD20 is a direct regulator of B-cell receptor signaling in the microenvironment of chronic lymphocytic leukemia
Year: 2018, type: Conference abstract
-
CD20 reguluje signalizaci přes B-buněčný receptor v mikroprostředí chronické lymfocytární leukémie
Year: 2018, type: Conference abstract
-
CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo
Year: 2018, type: Conference abstract
-
CLLEAR český registr pacientů s chronickou lymfocytární leukemií – kompletní analýza dat
Year: 2018, type: Conference abstract
-
C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies
International journal of hematology, year: 2018, volume: 108, edition: 6, DOI
-
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Lancet Oncology, year: 2018, volume: 19, edition: 6, DOI